Literature DB >> 12176358

Inhibition of retroviral pathogenesis by RNA interference.

Wen-Yuan Hu1, Christopher P Myers, Jennifer M Kilzer, Samuel L Pfaff, Frederic D Bushman.   

Abstract

BACKGROUND: RNA interference (RNAi) is a newly discovered cellular defense system that is known to suppress replication of genomic parasites in model organisms. It has been widely conjectured that RNAi may also serve as an antiviral system in vertebrates.
RESULTS: Retroviral infection could be initiated by electroporation of cloned Rous sarcoma virus (RSV) proviral DNA into the developing chick neural tube. Coelectroporation of proviral DNA and short double-stranded RNAs matching sequences of avain retroviruses, which were designed to induce RNAi against RSV, inhibited viral replication. Replication of RSV after electroporation resulted in disruption of embryonic development and early death, but this, too, could be suppressed by RNAi against the RSV genome. RNAi could also inhibit the growth of RSV and HIV in cell culture. Analysis of the step of the retroviral life cycle that is inhibited by RNAi revealed that it primarily prevented accumulation of the viral RNAs synthesized late during infection. RNA genomes introduced in viral particles early during infection were less sensitive.
CONCLUSIONS: RNAi can block retroviral infection in vertebrates. The tissue electroporation method described here should allow RNAi to be used widely to study gene function and control of infection in vertebrate animals.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12176358     DOI: 10.1016/s0960-9822(02)00975-2

Source DB:  PubMed          Journal:  Curr Biol        ISSN: 0960-9822            Impact factor:   10.834


  64 in total

1.  Tolerance for mutations and chemical modifications in a siRNA.

Authors:  Mohammed Amarzguioui; Torgeir Holen; Eshrat Babaie; Hans Prydz
Journal:  Nucleic Acids Res       Date:  2003-01-15       Impact factor: 16.971

Review 2.  Nucleic acid-based immune system: the antiviral potential of mammalian RNA silencing.

Authors:  Leonid Gitlin; Raul Andino
Journal:  J Virol       Date:  2003-07       Impact factor: 5.103

Review 3.  RNA interference: antiviral weapon and beyond.

Authors:  Quan-Chu Wang; Qing-He Nie; Zhi-Hua Feng
Journal:  World J Gastroenterol       Date:  2003-08       Impact factor: 5.742

4.  Uncoupling of RNAi from active translation in mammalian cells.

Authors:  Shuo Gu; John J Rossi
Journal:  RNA       Date:  2004-12-01       Impact factor: 4.942

Review 5.  RNA interference: the molecular immune system.

Authors:  Omar Bagasra; Kiley R Prilliman
Journal:  J Mol Histol       Date:  2004-08       Impact factor: 2.611

6.  Identification of effective siRNA against K-ras in human pancreatic cancer cell line MiaPaCa-2 by siRNA expression cassette.

Authors:  Wei Wang; Chun-You Wang; Ju-Hua Dong; Xiong Chen; Min Zhang; Gang Zhao
Journal:  World J Gastroenterol       Date:  2005-04-07       Impact factor: 5.742

7.  Lentiviral delivery of short hairpin RNAs protects CD4 T cells from multiple clades and primary isolates of HIV.

Authors:  Sang-Kyung Lee; Derek M Dykxhoorn; Priti Kumar; Shahin Ranjbar; Erwei Song; Laura E Maliszewski; Vanessa François-Bongarçon; Anne Goldfeld; N Manjunath Swamy; Judy Lieberman; Premlata Shankar
Journal:  Blood       Date:  2005-04-14       Impact factor: 22.113

8.  RNA interference-mediated virus clearance from cells both acutely and chronically infected with the prototypic arenavirus lymphocytic choriomeningitis virus.

Authors:  Ana B Sánchez; Mar Perez; Tatjana Cornu; Juan Carlos de la Torre
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

9.  Protocols for gene silencing in schistosomes.

Authors:  David Ndegwa; Greice Krautz-Peterson; Patrick J Skelly
Journal:  Exp Parasitol       Date:  2007-08-15       Impact factor: 2.011

Review 10.  RNA interference-based therapeutics for human immunodeficiency virus HIV-1 treatment: synthetic siRNA or vector-based shRNA?

Authors:  Sandesh Subramanya; Sang-Soo Kim; N Manjunath; Premlata Shankar
Journal:  Expert Opin Biol Ther       Date:  2010-02       Impact factor: 4.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.